PHAT News and Press, Phathom Pharmaceuticals Inc. From 12/16/20

FLORHAM PARK, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten publi...

Phathom Pharmaceuticals (PHAT) to offer and sell 2.25M shares of its common stock in an underwritten public offering. Underwriters have an option to purchase up to an additional 337.5k shares of common stock. Price is yet to be determined. For further details see: Phathom Pharma launche...

FLORHAM PARK, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, su...

Phathom Pharmaceuticals ([[PHAT]] +4.8%) plans to expand its vonoprazan development program into non-erosive reflux disease ((NERD)), a subcategory of gastroesophageal reflux disease and is characterized by reflux-related symptoms in the absence of esophageal mucosal erosions.As a next step i...

FLORHAM PARK, N.J., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced plans to expand its vonoprazan d...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadThe earnings calendar is almost bare in the week ahead, although reports from FedEx (NYSE:FDX) and Nike (NYSE:NKE) could ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Phathom Pharmaceuticals (PHAT) has completed patient enrollment in Phase 3 (PHALCON-EE) trial, evaluating vonoprazan for both the healing and maintenance of healing of erosive esophagitis as well as the relief of heartburn. Phathom exceeded the patient enrollment target of 1,000 patients, and...

FLORHAM PARK, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has completed patient en...